TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06172296: Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Sponsor: National Cancer Institute (NCI) · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 478 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,630,088

Rescue Site Savings

+$2,404,344

Unlock Full NCT06172296 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06172296 Rescue Dossier →